Abstract 2566
Background
Data on functional imaging parameters such as blood volume (BV) in metastatic renal cell carcinoma (mRCC) is limited. We assessed the association of baseline BV with survival outcome adjusted for baseline clinical factor in patients with mRCC.
Methods
BV was quantified using dynamic contrast-enhanced computed tomography in patients from two prospective studies; Angiogenesis Inhibitor Study (AIS) with pazopanib, sunitinib and temsirolimus and the Danish Renal Cancer Group Study-1 (Darenca-1) with interleukin-2, interferon alpha with or without bevacizumab. Data were analyzed using an Advanced Perfusion and Permeability Application softwareprogram, Phillips. BV was evaluated as a binary (above/below median) and as a continuous variable adjusted for treatment, gender, and individual IMDC factors. Association was evaluated using chi squared test for clinical factors, Cox regression for overall survival (OS) and progression-free survival (PFS), and logistic regression for objective response rate (ORR).
Results
Among 122 included patients, 105 patients had technically feasible scans and were included in the final analysis (AIS, N = 29 and Darenca-1, N = 76). Median BV was 32.87 mL * 100 g-1 (range 9.52 to 92.87). BV above median was associated with IMDC favorable risk group (p = 0.004), metastasis free interval > 1 year (p = 0.007) and male gender (p = 0.032). BV below median was associated with anemia (p = 0.040) and neutrophilia (p = 0.007). Patients with high vs. low baseline BV had longer PFS (12.5 vs. 5.6 months, p = 0.015) and longer OS (42.2 vs. 22.4 months, p = 0.001), respectively. In multivariate analysis, high baseline BV remained an independent favorable prognostic factor (OS: HR 0.49, 95% CI 0,30-0,78, p = 0.003, PFS: HR 0.64; 95% CI 0,42-0,97, p = 0.040). BV analyzed as a continuous variable was also associated with OS in multivariate analysis (HR 0.98, 95% CI 0,96-1,00, p = 0,017). No association was found between BV and ORR (OR 1.56; 95% CI 0,67-3,63, p = 0.3).
Conclusions
High baseline BV, obtained using functional imaging, is a new independent favorable prognostic factor associated with longer PFS and OS in patients with mRCC. Further research in functional imaging is encouraged.
Clinical trial identification
NCT01274273 (Darenca-1 Study).
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Phillips Healthcare provided the software used for DCE-CT analysis Roche and Novartis supported the clinical part of the study financially - but were however not invovled in the imaging analysis.
Disclosure
A. Drljevic-Nielsen: Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: BMS. F. Donskov: Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
3128 - Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
Presenter: Sumita Trivedi
Session: Poster Display session 3
Resources:
Abstract
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract